HATS off to KAT6A/B inhibitors: A new way to target estrogen-receptor-positive breast cancer.

Jeselsohn, Rinath; Polyak, Kornelia

Jeselsohn, Rinath; Polyak, Kornelia.

Afiliación

Jeselsohn R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
Polyak K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA. Electronic address: kornelia_polyak@dfci.harvard.edu.

Cell Chem Biol ; 30(10): 1183-1185, 2023 10 19.

Article en En | MEDLINE | ID: mdl-37863030

RESUMEN

Inhibitors for the KAT6 family of histone acetyltransferases (HATs) have been actively pursued due to the oncogenic roles of KAT6A in human cancer. CTx-648 is a novel KAT6A/B inhibitor with excellent pharmacokinetic properties and in vivo efficacy that represents a promising new treatment strategy for estrogen-receptor-positive breast cancer.

Asunto(s)

Neoplasias de la Mama; Humanos; Femenino; Neoplasias de la Mama/tratamiento farmacológico; Histona Acetiltransferasas; Estrógenos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama Límite: Female / Humans Idioma: En Revista: Cell Chem Biol Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google